In order to elucidate mechanisms underlying adverse effects of antipsychotic use in dementia we generated gene expression signatures for three antipsychotics representing  a  range  of  mechanisms  of  action  relevant  to  the  current  landscape  of  drug development  and  clinical  use  in  dementia:  amisulpride  (primarily  a  D2/D3  antagonist), risperidone  (primarily  a  5HT2A/D2  antagonist)  and  volinanserin  (highly  selective  5HT2A inverse agonist). We  reported  that  the antipsychotic signatures would be score positively with conditions and diseases related to known side effects of their use in dementia such as cardiovascular and infectious diseases. SOURCE: Yasaman Malekizadeh (yasaman.malekizadeh@gmail.com) -  University of Exeter

Pluto Bioinformatics

GSE149611: Assess the effects of antipsychotic use on gene expression changes in dementia